Bank Julius Baer & Co. Ltd Zurich Sells 3,513 Shares of Amgen Inc. $AMGN

Bank Julius Baer & Co. Ltd Zurich trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 17.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 16,068 shares of the medical research company’s stock after selling 3,513 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Amgen were worth $5,275,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. West Family Investments Inc. boosted its stake in Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares during the last quarter. Viawealth LLC boosted its stake in Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after acquiring an additional 30 shares during the last quarter. LOM Asset Management Ltd boosted its stake in Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after acquiring an additional 30 shares during the last quarter. Smith Salley Wealth Management boosted its stake in Amgen by 0.3% in the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock valued at $3,530,000 after acquiring an additional 30 shares during the last quarter. Finally, Evergreen Private Wealth LLC boosted its stake in Amgen by 4.0% in the fourth quarter. Evergreen Private Wealth LLC now owns 785 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 30 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $326.31 on Friday. The stock has a market capitalization of $176.10 billion, a P/E ratio of 22.71, a PEG ratio of 3.38 and a beta of 0.44. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm’s 50 day moving average is $349.17 and its 200 day moving average is $342.99. Amgen Inc. has a 12 month low of $267.73 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.15%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AMGN. Barclays began coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price on the stock. Morgan Stanley set a $332.00 target price on shares of Amgen in a research note on Friday, May 1st. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Citigroup boosted their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Finally, UBS Group boosted their target price on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $356.15.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.